---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-039650"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:48:22.951406+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength

## Summary
- TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.
- Olezarsen Phase 3 sHTG: 72% TG reduction, 85% AP reduction; sNDA by year-end 2025.
- Zilganersen positive pivotal in Alexander disease; NDA submission planned Q1 2026.
- Total revenue guidance raised to $875-900M; non-GAAP op loss guided to $275-300M.
- Cash and investments $2.2B as of Sep 30; DAWNZERA launched in August 2025.

## SEC filing metadata
- accession: 0001140361-25-039650
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036125039650/0001140361-25-039650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036125039650/ef20057869_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-039650
- JSON: https://secwatch.observer/filing/0001140361-25-039650.json
- Plain text: https://secwatch.observer/filing/0001140361-25-039650.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.